
# Thrombophilia and the risk of arterial thrombosis

Dr C Brammer


#### Summary

- Basic physiology
  - coagulation vs. anticoagulation
- Venous thrombosis and thrombophilia
- Arterial disease and thrombophilia


### Basic Physiology




### Basic Physiology




#### Natural Anticoagulants



### Natural Anticoagulants





#### The Concept of Thrombophilia

"A disorder of haemostasis that increases the probability of thrombosis"

70% of venous thromboses have an identifiable precipitant

30% do not and are "spontaneous"

### Circumstantial Triggering

The interaction of two or more intrinsic or extrinsic influences as the "trigger" for thrombosis.

#### Extrinsic Influences

- General anaesthesia/surgery
- Trauma
- Oestrogen therapy
- Air travel
- Intravenous injection/cannulation
- (Smoking)

#### Intrinsic influences

- Congenital
  - AT deficiency
  - PC/PS deficiency
  - Dysfibrinogenaemia
  - APCR/FVLM
  - PTGM
  - others

#### Acquired

Antiphospholipid syndrome

Obesity

Pregnancy

Malignancy

Myeloproliferative disorders


others

# Natural anticoagulant deficiencies

DISORDER	Homozygous state?	Overall gene prevalence	Frequency in thrombotics	Relative risk of VTE
Anti- thrombin deficiency	(no)	0.02%	0.5-1.0%	25-50
Protein C deficiency	Yes	0.2-0.3%	3.0%	10-15
Protein S deficiency	Yes	1.3-2.1%?	3.0%	Mild?

#### Other heritable thrombophilias

DISORDER	Homozygous state?	Overall gene prevalence	Frequency in thrombotics	Relative risk of VTE
Factor V Leiden mutation	Yes	2-15%	20-50%	3-8 (80 if HZ)
Prothrombin gene variant	Yes	2.0%	6.0%	3



#### Antiphospholipid Antibodies

- Common finding
  - significant proportion of healthy (esp. elderly)
     population
  - most never thrombose
  - may be transient
- Uncommon cause of severe thrombophilia
- Complex physiology

#### Antiphospholipid Antibodies

- As most APL antibodies are not pathogenic,
   and many are transient, be strict about the
   diagnostic criteria
  - 1-5% of healthy controls
- Possibly the only thrombophilia which makes a difference to management of a first thrombosis

#### Antiphospholipid syndrome

- Association of a thrombotic tendency
  - venous or arterial thrombosis
  - recurrent (3+) miscarriages
- with the persistence of one or more antiphospholipid antibodies
  - LA confirmed by two different tests, or IgG or IgM ACA by ELISA
  - repeated after 6 weeks

#### Factor VIII

- Raised FVIII levels are associated with an increased risk of venous thrombosis
- If FVIII >150iu/dl, relative risk of VTE is
   4.8 compared with if FVIII <100iu/dl</li>
- Is this the commonest thrombophilia?
- Need to exclude acute phase reaction as a cause of raised FVIII
- Genetic determinant?

#### Hyperhomocysteinaemia

- Non-protein forming amino acid
- Product of the metabolic processing of methionine

#### Fibrinogen

- No clear cut association with venous thrombosis
- Possible association between raised FIX and XI levels and venous thrombosis
- No evidence of a genetic element as yet

## What difference does a positive test make?

- First thrombosis does it influence immediate management?
- Does it influence duration of therapy?
- Does it make a difference to advice regarding high risk exposure?
  - i.e. surgery, OCP/HRT, pregnancy, LHAF

## What difference does a positive test make?

- Screening asymptomatic patients
  - a positive test is not an indication for anticoagulation
  - most will never thrombose
- Would a positive test modify lifestyle/risk management advice?
  - controversial

#### So why do it?

- Patient curiosity
- Future reference
- Possibly will influence advice
  - COCP/HRT
  - surgery
  - pregnancy
  - ?duration/intensity of anticoagulation

Is thrombophilia screening of value when investigating arterial disease?

## National Clinical Guidelines for Stroke

"It is likely that local services will wish to develop local guidelines for:


5. investigation of the underlying cause of stroke; "








The charity for people with diabetes





#### Natural Anticoagulant Pathway

- AT, PC and PS deficiencies, APCR/FVLM,
   PTGV
- Any evidence of an association with stroke or ischaemic heart disease is anecdotal
- No genuine justification for testing

#### Antiphospholipid Syndrome

- Clear association between presence of antiphospholipid antibodies and first VTE, first MI and recurrent stroke
  - VTE>CVA>MI
- Enough to justify primary prophylaxis?
- Enough to justify secondary prophylaxis?

#### Hyperhomocysteinaemia

- Association between homocystinuria and atherosclerosis reported in 1969
- Is there an association between moderately raised homocysteine levels and CVA and IHD?
- Relative risk of MI 1.7, CVA 2.5, PVD 6.8
- Increase in plasma homocysteine of 5μmol/l
   associated with 33% increase in vascular risk

#### Hyperhomocysteinaemia

- Genetic influence
  - MTHFR or CBS heterozygosity
  - Not independently associated with vascular risk
- Dietary influence
  - B12, B6 and Folate supplementation will lower homocysteine levels moderately (2µmol/l)
- Is this reduction associated with a reduced risk?
  - VISP and VITATOPS studies in stroke

#### Coagulation factor excess

- Raised clottable fibrinogen appears to be associated with increased mortality from CHD
- Clauss assay
- Due to effect on whole blood viscosity?
  - Haematocrit also associated
- No evidence of a genetic effect

## Summary of thrombophilia and arterial disease

- Limited thrombophilia screening may be of value in investigation of stroke, IHD and
   PVD in selected patients
- "Young" patients
  - under 40(?) for MI, under 60(?) for CVA
  - esp. if no other risk factors
  - only in non smokers for PVD

## Summary of thrombophilia and arterial disease

- Some tests of no value
  - PC, PS and AT assays, APCR/FVLM, PTGV, factor VIII assay
- Others more valuable?
  - Lupus anticoagulant/anticardiolipin antibodies
  - Homocysteine

# So choose your patients (and tests) carefully...

- Venous thromboembolic disease
  - Under 55
  - PC, PS, AT, VIII assays
  - APCR +/- FVLM
  - PTGV
  - VIII
  - LA/ACA
  - Homocysteine

- Arterial disease
  - under 40 for IHD
  - under 60 for CVA
  - ?PVD if non smoker
  - LA/ACA
  - Homocysteine

